Cargando…

Intracerebral hemorrhage: who gets tested for methamphetamine use and why might it matter?

BACKGROUND: Methamphetamine use is an emerging risk factor for intracerebral hemorrhage (ICH). The aim of this study was to investigate the use of urine drug screen (UDS) for identifying methamphetamine-associated ICH. METHODS: This is a retrospective, single-center study of consecutive patients hos...

Descripción completa

Detalles Bibliográficos
Autores principales: Osman, Sahar, Zhu, Zhu, Farag, Mark, Groysman, Leonid, Dastur, Cyrus, Akbari, Yama, Stern-Nezer, Sara, Stradling, Dana, Yu, Wengui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592363/
https://www.ncbi.nlm.nih.gov/pubmed/33109106
http://dx.doi.org/10.1186/s12883-020-01967-y
_version_ 1783601169454596096
author Osman, Sahar
Zhu, Zhu
Farag, Mark
Groysman, Leonid
Dastur, Cyrus
Akbari, Yama
Stern-Nezer, Sara
Stradling, Dana
Yu, Wengui
author_facet Osman, Sahar
Zhu, Zhu
Farag, Mark
Groysman, Leonid
Dastur, Cyrus
Akbari, Yama
Stern-Nezer, Sara
Stradling, Dana
Yu, Wengui
author_sort Osman, Sahar
collection PubMed
description BACKGROUND: Methamphetamine use is an emerging risk factor for intracerebral hemorrhage (ICH). The aim of this study was to investigate the use of urine drug screen (UDS) for identifying methamphetamine-associated ICH. METHODS: This is a retrospective, single-center study of consecutive patients hospitalized with spontaneous ICH from January 2013 to December 2017. Patients were divided into groups based on presence of UDS. The characteristics of patients with and without UDS were compared. Factors associated with getting UDS were explored using multivariable analyses. RESULTS: Five hundred ninety-six patients with ICH were included. UDS was performed in 357 (60%), and positive for methamphetamine in 44 (12.3%). In contrast, only 19 of the 357 patients (5.3%) had a documented history of methamphetamine use. Multivariable analysis demonstrated that patients screened with UDS were more likely to be younger than 45 (OR, 2.24; 95% CI, 0.26–0.78; p = 0.004), male (OR, 1.65; 95% CI, 0.44–0.84; p = 0.003), smokers (OR, 1.74; 95% CI, 1.09–2.77; p <  0.001), with history of methamphetamine use (OR, 10.48; 95% CI, 2.48–44.34; p <  0.001), without diabetes (OR 1.47; 95% CI, 0.471–0.975; p = 0.036), not on anticoagulant (OR, 2.20; 95% CI, 0.26–0.78; p = 0.004), with National Institutes of Health Stroke Scale (NIHSS) > 4 (OR, 1.92; 95%CI, 1.34–2.75; p <  0.001), or require external ventricular drain (EVD) (OR, 1.63; 95%CI, 1.07–2.47; p = 0.021. There was no significant difference in race (p = 0.319). Reported history of methamphetamine use was the strongest predictor of obtaining a UDS (OR,10.48). Five percent of patients without UDS admitted history of use. CONCLUSION: UDS identified 12.3% of ICH patients with methamphetamine use as compared to 5.3% per documented history of drug use. There was no racial bias in ordering UDS. However, it was more often ordered in younger, male, smokers, with history of methamphetamine use, without diabetes or anticoagulant use.
format Online
Article
Text
id pubmed-7592363
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-75923632020-10-29 Intracerebral hemorrhage: who gets tested for methamphetamine use and why might it matter? Osman, Sahar Zhu, Zhu Farag, Mark Groysman, Leonid Dastur, Cyrus Akbari, Yama Stern-Nezer, Sara Stradling, Dana Yu, Wengui BMC Neurol Research Article BACKGROUND: Methamphetamine use is an emerging risk factor for intracerebral hemorrhage (ICH). The aim of this study was to investigate the use of urine drug screen (UDS) for identifying methamphetamine-associated ICH. METHODS: This is a retrospective, single-center study of consecutive patients hospitalized with spontaneous ICH from January 2013 to December 2017. Patients were divided into groups based on presence of UDS. The characteristics of patients with and without UDS were compared. Factors associated with getting UDS were explored using multivariable analyses. RESULTS: Five hundred ninety-six patients with ICH were included. UDS was performed in 357 (60%), and positive for methamphetamine in 44 (12.3%). In contrast, only 19 of the 357 patients (5.3%) had a documented history of methamphetamine use. Multivariable analysis demonstrated that patients screened with UDS were more likely to be younger than 45 (OR, 2.24; 95% CI, 0.26–0.78; p = 0.004), male (OR, 1.65; 95% CI, 0.44–0.84; p = 0.003), smokers (OR, 1.74; 95% CI, 1.09–2.77; p <  0.001), with history of methamphetamine use (OR, 10.48; 95% CI, 2.48–44.34; p <  0.001), without diabetes (OR 1.47; 95% CI, 0.471–0.975; p = 0.036), not on anticoagulant (OR, 2.20; 95% CI, 0.26–0.78; p = 0.004), with National Institutes of Health Stroke Scale (NIHSS) > 4 (OR, 1.92; 95%CI, 1.34–2.75; p <  0.001), or require external ventricular drain (EVD) (OR, 1.63; 95%CI, 1.07–2.47; p = 0.021. There was no significant difference in race (p = 0.319). Reported history of methamphetamine use was the strongest predictor of obtaining a UDS (OR,10.48). Five percent of patients without UDS admitted history of use. CONCLUSION: UDS identified 12.3% of ICH patients with methamphetamine use as compared to 5.3% per documented history of drug use. There was no racial bias in ordering UDS. However, it was more often ordered in younger, male, smokers, with history of methamphetamine use, without diabetes or anticoagulant use. BioMed Central 2020-10-27 /pmc/articles/PMC7592363/ /pubmed/33109106 http://dx.doi.org/10.1186/s12883-020-01967-y Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Osman, Sahar
Zhu, Zhu
Farag, Mark
Groysman, Leonid
Dastur, Cyrus
Akbari, Yama
Stern-Nezer, Sara
Stradling, Dana
Yu, Wengui
Intracerebral hemorrhage: who gets tested for methamphetamine use and why might it matter?
title Intracerebral hemorrhage: who gets tested for methamphetamine use and why might it matter?
title_full Intracerebral hemorrhage: who gets tested for methamphetamine use and why might it matter?
title_fullStr Intracerebral hemorrhage: who gets tested for methamphetamine use and why might it matter?
title_full_unstemmed Intracerebral hemorrhage: who gets tested for methamphetamine use and why might it matter?
title_short Intracerebral hemorrhage: who gets tested for methamphetamine use and why might it matter?
title_sort intracerebral hemorrhage: who gets tested for methamphetamine use and why might it matter?
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592363/
https://www.ncbi.nlm.nih.gov/pubmed/33109106
http://dx.doi.org/10.1186/s12883-020-01967-y
work_keys_str_mv AT osmansahar intracerebralhemorrhagewhogetstestedformethamphetamineuseandwhymightitmatter
AT zhuzhu intracerebralhemorrhagewhogetstestedformethamphetamineuseandwhymightitmatter
AT faragmark intracerebralhemorrhagewhogetstestedformethamphetamineuseandwhymightitmatter
AT groysmanleonid intracerebralhemorrhagewhogetstestedformethamphetamineuseandwhymightitmatter
AT dasturcyrus intracerebralhemorrhagewhogetstestedformethamphetamineuseandwhymightitmatter
AT akbariyama intracerebralhemorrhagewhogetstestedformethamphetamineuseandwhymightitmatter
AT sternnezersara intracerebralhemorrhagewhogetstestedformethamphetamineuseandwhymightitmatter
AT stradlingdana intracerebralhemorrhagewhogetstestedformethamphetamineuseandwhymightitmatter
AT yuwengui intracerebralhemorrhagewhogetstestedformethamphetamineuseandwhymightitmatter